New Key Statistics Module, Z-Score and F-Score
NAS:FULC Key Ratios
| Market Cap $ M | 443.78 |
| Enterprise Value $ M | 217.75 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 1.88 |
| Price/Sales | 162.80 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 2.00 |
| EPS (TTM) $ | -1.58 |
| Beneish M-Score | -0.12 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | 10.60 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -1.97 |
| EV-to-EBITDA | -2.01 |
| PEG | -- |
| Shares Outstanding M | 62.15 |
| Net Margin (%) | -3,470.05 |
| Operating Margin % | -3,945.24 |
| Pre-tax Margin (%) | -3,470.05 |
| Quick Ratio | 17.71 |
| Current Ratio | 17.71 |
| ROA % (ttm) | -35.15 |
| ROE % (ttm) | -38.59 |
| ROIC % (ttm) | -540.64 |
| Dividend Yield % | -- |
| Altman Z-Score | 8.88 |
FULC Number of Guru Trades
FULC Volume of Guru Trades
Gurus Latest Trades with NAS:FULC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:FULC is held by these investors
Total 1
Fulcrum Therapeutics Inc Insider Transactions
No Available Data
News about NAS:FULC
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers